Core Viewpoint - Xinda Biopharmaceutical has entered into a global strategic collaboration with Takeda Pharmaceutical to accelerate the development of its next-generation IO and ADC therapies, with a total deal value potentially reaching $11.4 billion [1] Group 1: Collaboration Details - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001 [1] - Xinda Biopharmaceutical and Takeda will jointly develop IBI363 globally, with Takeda leading the development efforts in the U.S. [1] - Xinda grants Takeda commercialization rights for IBI363 outside of Greater China and the U.S., while Takeda receives exclusive rights for IBI343 outside of Greater China [1] Group 2: Financial Aspects - Xinda will receive an upfront payment of $1.2 billion, which includes a strategic equity investment of $100 million [1] - The company is eligible for up to $10.2 billion in potential milestone payments, making the total deal value potentially reach $11.4 billion [1] - Xinda will also receive a share of potential sales for each candidate drug outside of Greater China, with a profit-sharing model for IBI363 in the U.S. [1]
信达生物：与武田制药达成全球战略合作，交易总金额最高可达114亿美元